Drug intelligence / Profile preview

ABC-201

Development stage: Preclinical
Lead developer: ABCELY
Modality: Antibody-Based Therapeutics

Overview

ABC-201 is a preclinical-stage secretory IgA (sIgA) antibody being developed by ABCELY for the treatment of endometriosis. Secretory IgA is the primary antibody class found in mucosal secretions and is characterized by its dimeric structure and resistance to proteolysis, making it suitable for targeting mucosal or inflammatory environments. While the specific biological target of ABC-201 is currently undisclosed (referred to as 'Target X'), the therapeutic approach aims to utilize the unique properties of sIgA to modulate the disease process in endometriosis.

Beyond the preview

Go deeper on ABC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABC-201.

Explore the full profile